USPTO serial 79371640
GENOMIGON
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 25, 2025
- Examiner
- OH, HYUN-JUNG
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with GENOMIGON?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Catherine F. Hoffman
Catherine F. Hoffman Baker, Donelson, Bearman, Caldwell200 E. Broward Blvd., Suite 2000Fort Lauderdale, FL 33301United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the treatment of malignant tumor diseases and malignant and benign blood diseases, and infectious diseases; diagnostic preparations and materials for medical purposes; diagnostic substances for medical use; diagnostic testing materials for medical use, namely, medical diagnostic test media in the form of, strips, threads, liquids, gels, and serums, for measuring, biomarkers in malignant diseases and hereditary diseases on a genetic basis or protein basis, gene variants in hereditary diseases and malignant diseases; medical diagnostic test strips for blood analysis, urine analysis, and saliva analysis; biotechnological preparations for medical use in the nature of pharmaceutical preparations for the treatment of cancer, malignant and non-malignant blood diseases and hereditary diseases; medicine, namely, cytostatics for medical purposes, antibodies for medical purposes, antibody-drug conjugates, therapeutically modified lymphocytes, mixed hormone preparations, preparations for the targeted treatment of malignant and non-malignant diseases in the nature of targeted delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals that inhibit, activate or modulate regulatory cascades in malignant and non-malignant diseases or the microenvironment such as tyrosine kinase inhibitors, antibodies, antibody drug conjugates, immune checkpoint inhibitors, T cell engagers, modified effector cell preparations such as CAR-T cells, bispecific or multispecific antibodies, antibody-nuclide conjugates; biopharmaceuticals for medical purposes in the nature of pharmaceutical preparations for the treatment of, malignant blood diseases, benign blood diseases, malignant solid tumors, benign solid tumors, cancer and hereditary diseases; biopharmaceuticals for medical purposes in the nature of pharmaceutical preparations for healing or alleviating ailments and reducing symptoms of blood diseases; biological preparations for medical purposes, namely, biological preparations for the treatment of, malignant blood diseases, benign blood diseases, malignant solid tumors, and benign solid tumors; all the aforesaid goods relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine | ACTIVE | — |
| 010 | Genetic testing apparatus for medical purposes; diagnostic equipment and instruments for medical purposes for the analysis of body fluids, benign and malignant tissue and blood, protein structures of tumors, genetic code of tissue and blood cells, analysis of blood cells, blood plasma and blood serum; medical apparatus for carrying-out diagnostic tests for medical purposes for cancer cells, leukemia cells, benign and malignant cells of humans and animals, genetic material; medical testing instruments for medical diagnostic purposes for blood sugar levels, cancer cells, genetic material; electromedical diagnostic instruments, namely, electromedical rehabilitative and pain management products for clinical and home use, namely, electrical nerve and muscle stimulators, ultrasonic stimulators, magnet therapy stimulators and laser therapy stimulators; radiation instruments, for medical purposes, namely, radiation therapy devices; medical radiation apparatus for medical purposes; medical apparatus for the treatment of cancer; apparatus for DNA and RNA testing for medical purposes; all the aforesaid goods relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine | ACTIVE | — |
| 042 | Scientific analysis in the field of pharmaceuticals, and medical devices; scientific research in the field of genetics, hematology, and oncology; genetic scientific research; pharmaceutical research services; clinical research in the field of radiology, radiotherapy, surgical medicine, oncological system therapy of malignant and benign diseases, and infectious diseases; research relating to biotechnology; medical research; computer aided diagnostic testing services, namely, diagnostic services for others for scientific research purposes; design and development of medical diagnostic apparatus; design and development of medical technology; development of pharmaceutical preparations and medicines; provision of information and data relating to medical and veterinary research and development; consultancy relating to research and development in the field of therapeutics; providing scientific research information in the field of medical disorders and their treatment; laboratory testing and analysis for medical research purposes in the field of bacteriology, chemistry, life science, molecular genetics, protein diagnostics, oncology, hematology, radiology, and radiotherapy; biomedical assay services and development for the analysis of body fluids, tissue samples and fluids and blood and blood products for benign and malignant diseases in the field of diagnostic preparations, implements and medication; all the aforesaid services relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine | ACTIVE | — |
| 044 | Medical services; medical analysis services relating to disease management, disease diagnosis services, disease prognosis; medical laboratory services for the analysis of samples taken from patients; health screening services in the field of malignant tumor diseases, benign tumor diseases, malignant blood diseases, benign blood diseases, hereditary diseases, coagulation disorders; providing medical information in the healthcare sector; medical consultations; arranging of medical treatment in the field of oncology, hematology, genetics, gene therapies, targeted therapy, cell therapies; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; all the aforesaid services relating to the fields of oncology, chemotherapy, molecular genetics, molecular medicine | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Dirk Hempel
- Other trademarks owned by Dirk Hempel
- Other trademarks owned by Dirk Hempel
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named GENOMIGON
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 15, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 27, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 7, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 7, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 25, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 25, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 25, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 7, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 7, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 1, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 10, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 10, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 10, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 10, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 10, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 5, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 5, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 5, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Nov 23, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 6, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 6, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jun 11, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 11, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 11, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 7, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 7, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 7, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 4, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| Nov 15, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 15, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 14, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 13, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 3, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 16, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 12, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 8, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |